you still with us over there in the states Biotechmaster or have you finished ramping this puppy. What no more "see you at +$20 by the end of the year" blah blah blah. Your indepth analysis of this stock is greatly missed.
the lasted announcement was not well received getting smashed nearly 22% in the US last night. Being "encouraged" by the results is code for "hmmm could have been better" imo. whilst this small test (37)was primarily focused on the safety of Iluvien i guess the market was not happy that the drug did help the low dose patients to focus! I hope the results of the low dose in the 1000 patient trial is more promising.
whats your thoughts biotech?
Add to My Watchlist
What is My Watchlist?